The prilocaine is a very common local anesthetic that has the disadvantage of being metabolized to o-toluidine, a human carcinogen. Hyperbaric 2% prilocaine (HP), recently developped, is increasingly used for spinal anesthesia in ambulatory surgery. But the formation of carcinogenic metabolites induced by the hyperbaric prilocaine is not yet known. The aim of this study is to investigate whether the intrathecal administration of 50 mg hyperbaric prilocaine induces also the formation of carcinogenic complexes such as urinary o-toluidine and hemoglobin adducts from o-toluidine in blood.
Study Type
OBSERVATIONAL
Enrollment
10
Braine-l'Alleud Hospital
Braine-l'Alleud, Belgium
Hemoglobin adducts from o-toluidine in blood
Hemoglobin adducts from o-toluidine in blood is measured before surgery (at admission)
Time frame: Time 0 (before surgery)
Hemoglobin adducts from o-toluidine in blood
Hemoglobin adducts from o-toluidine in blood is measured at 24 hours after intrathecal prilocaine injection
Time frame: Time 24 hours after intrathecal prilocaine injection
Urinary o-toluidine
Urinary o-toluidine is measured before surgery (at admission)
Time frame: Time 0 (before surgery)
Urinary o-toluidine
Urinary o-toluidine is measured at 6 hours after intrathecal prilocaine injection
Time frame: Time 6 hours after intrathecal prilocaine injection
Urinary o-toluidine
Urinary o-toluidine is measured at 12 hours after intrathecal prilocaine injection
Time frame: Time 12 hours after intrathecal prilocaine injection
Urinary o-toluidine
Urinary o-toluidine is measured at 24 hours after intrathecal prilocaine injection
Time frame: Time 24 hours after intrathecal prilocaine injection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.